(Q42995429)

12 November 2017

Insulin resistance predicts rapid virologic response to peginterferon/ribavirin combination therapy in hepatitis C genotype 4 patients (English)

1 reference

12 November 2017

0 references

1 reference

1 reference

1 reference

1 reference

2

Mohammed Eslam

1 reference

12 November 2017

Mahmoud Khattab

1

1 reference

12 November 2017

Mohammed Ahmed Sharwae

3

1 reference

12 November 2017

Mohammed Shatat

4

1 reference

12 November 2017

Ahmed Ali

5

1 reference

12 November 2017

Lamia Hamdy

6

1 reference

12 November 2017

language of work or name

English

0 references

publication date

16 March 2010

1 reference

The American Journal of Gastroenterology

12 November 2017

1 reference

12 November 2017

105

1 reference

12 November 2017

9

1 reference

12 November 2017

1970-1977

1 reference

Improved response to ribavirin interferon combination compared with interferon alone in patients with type 4 chronic hepatitis C without cirrhosis

12 November 2017

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.110

Infection with hepatitis C virus genotype 4 is associated with a poor response to interferon-alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.110

Interferon therapy in patients with chronic hepatitis C and schistosomiasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.110

Hepatitis C genotype 4: What we know and what we don't yet know.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.110

Pegylated interferon and ribavirin therapy for chronic hepatitis C virus genotype 4 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.110

Pegylated interferon alpha-2b plus ribavirin in patients with genotype 4 chronic hepatitis C: The role of rapid and early virologic response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.110

Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.110

Insulin resistance plays a significant role in liver fibrosis in chronic hepatitis C and in the response to antiviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.110

The impact of insulin resistance, serum adipocytokines and visceral obesity on steatosis and fibrosis in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.110

Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.110

An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.110

Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.110

Diagnosis, management, and treatment of hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.110

Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.110

Hepatitis C virus RNA kinetics during the initial 12 weeks treatment with pegylated interferon-alpha 2a and ribavirin according to virological response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.110

Insulin resistance impairs rapid virologic response in HIV/hepatitis C virus coinfected patients on peginterferon-alfa-2a

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.110

Insulin resistance and response to therapy in patients infected with chronic hepatitis C virus genotypes 2 and 3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.110

Non-response to antiviral therapy is associated with obesity and increased hepatic expression of suppressor of cytokine signalling 3 (SOCS-3) in patients with chronic hepatitis C, viral genotype 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.110

Virus-induced over-expression of protein phosphatase 2A inhibits insulin signalling in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.110

Targeting host factors: A novel rationale for the management of hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.110

Pioglitazone improves virological response to peginterferon alpha-2b/ribavirin combination therapy in hepatitis C genotype 4 patients with insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.110

21 January 2018

Identifiers

DOI

10.1038/AJG.2010.110

1 reference

12 November 2017

1 reference